Blogs | Multibagger Shares

April 20, 2026

Hero Header with Title owner Earnings and Subtitle the Buffett Adjustment That Reveals True Cash Profits over a Dark Blue Gradient Background Plus a Colorful Donut Chart Labeled fy25 Reinvested Centered Below

Owner Earnings: The Buffett Adjustment That Reveals True Cash Profits

Warren Buffett's 1986 owner-earnings formula adjusts reported net profit by adding back non-cash charges and subtracting maintenance capex and working-capital needs. Applied to four Indian businesses — Asian Paints, Pidilite, Nestlé India, and Titan Biotech — the arithmetic reveals very different cash-conversion profiles and gives retail investors a more honest lens than reported PAT alone.

April 19, 2026

Segment-Wise Revenue Breakdown

Titan Biotech disclosed only one primary operating segment in FY25, a quiet but powerful sign that the business remains easier to understand and monitor than many small-cap peers.

April 19, 2026

Hero Header for a Article Titled overconfidence Bias with a Subtitle About Indian Traders Decorative Blue Background with Green Accents

Overconfidence Bias: Why 93% of Indian F&O Traders Lose Money — How Barber & Odean’s Landmark Research, Validated by SEBI’s 2024 Evidence, Explains the Zerodha-Groww Revolution and the Anti-Overconfidence Checklist Every Serious Long-Term Investor Must Adopt

Barber & Odean's Nobel-adjacent 2000 study, validated by SEBI's 2024 evidence that ~93% of Indian retail F&O traders lose money, explains the meta-bias that makes every other cognitive error worse — and the 8-question pre-trade checklist that disarms it.

April 19, 2026

Board Composition and Corporate Governance

Titan Biotech ended FY25 with an 11-member board, four independent directors, an independent chair, and 14 board meetings - a governance structure that merits serious attention from long-term investors.